

WRITTEN DIRECTIVE PROGRAM RADIOPHARMACEUTICAL SECTION REVIEW

Please note the following about your Written Directive Program:

- Reconfigured from previous Quality Management Program on 10/24/03 as required by the U.S. Nuclear Regulatory Commission (NRC) 10 CFR 35.40 and 35.41.

- Impacts the usage of: ^{131}I as **Sodium Iodide only** in amounts greater than **30 μCi for either diagnostic or therapeutic uses.**

Any radiopharmaceutical used for therapeutic purposes such as ^{32}P , ^{89}S , ^{90}Y , ^{153}Sm , Zevalin, Bexxar etc.

- A “**Written Directive**” (prescription) is required to be issued to the Nuclear Medicine technical staff from an authorized user (Nuclear Medicine Physician) as listed on your NRC License **prior** to the initiation of the procedure.

- The Written Directive for Iodine-131 must contain the following in a clear manner:

1. Patient Name
2. Activity to be administered
3. Signature of Authorized User and Date

- The Written Directive for all other radiopharmaceuticals must contain the following in a clear manner:

1. Patient Name
2. The Radioactive Drug
3. Activity to be administered
4. The route of administration
5. Signature of Authorized User and Date

If any of the above information is unclear or missing **STOP** and seek clarification.

- The patient must be positively identified prior to administration.

It is not required that the identification process is documented but it is highly advisable and useful to do so. Additionally this information is needed for evaluation in the audit process to evaluate program effectiveness.

- **Written procedures** must exist and be implemented for assurance that the written directive is followed and patient identification is made at a minimum.
- The program additionally includes all types of brachytherapy(sealed sources), teletherapy and gamma stereotactic radiosurgery.